This is a structural separation of IP assets into a new entity (Lunai). Monitor for stockholder approval events enabling conversion of the Series B Preferred Stock and for any development milestones from Lunai, especially in biodefense and Alzheimer's. The asset transfer from Autotelic signals pipeline expansion but with heavily contingent equity compensation; watch for uplisting catalysts.
Price Chart
Executive Summary
Oncotelic Therapeutics completed a multi-step transaction (May 1, 2026) contributing its patent portfolio to Lunai Bioworks via a triangular merger, receiving $12.5M stated value in Series B Convertible Preferred Stock of Lunai. Simultaneously, OTLC retained a perpetual, exclusive license to the IP for all fields except biodefense and Alzheimer's, and acquired additional assets from Autotelic Inc. in exchange for 10% of fully diluted shares upon uplisting. No cash changed hands; the restructuring separates certain IP pathways without immediate operational impact.
Key Financial Metrics
Key Facts
- Oncotelic Inc. contributed its patent portfolio to Neurobridge IP Holdings, which then merged into a Lunai subsidiary.
- Consideration: 5 shares of Lunai Series B Preferred Stock with aggregate stated value of $12,500,000; convertible into 8,333,333 shares of Lunai common at $1.50 per share only after stockholder approval.
- OTLC received a perpetual, exclusive, royalty-free license to use the IP in all fields except biodefense and Alzheimer's disease.
- Autotelic Inc. (related to CEO Dr. Trieu) transferred additional drug assets to OTLC in exchange for 10% of fully diluted shares upon a future NYSE/NASDAQ uplisting.
- No cash consideration was paid or received in any of these transactions.
- The Series B Preferred Stock has a 4.99% beneficial ownership limitation and no voting rights.
Financial Impact
No cash impact; OTLC recorded a $12.5M stated value equity interest in Lunai, convertible into 8.3M shares at $1.50/share contingent on stockholder approval. Future dilution risk from 10% share issuance to Autotelic upon uplisting.
Risk Factors
- Conversion of Series B Preferred into common stock is blocked until stockholder approval, which may not be obtained.
- Future dilution when 10% of fully diluted shares are issued to Autotelic upon uplisting.
- Complex transaction structure may lead to governance or Nasdaq compliance challenges.
- No revenue or earnings data; financial impact is unclear until Lunai's operations generate results.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-021306 |
| Exhibit: ex10-2.htm | 0001493152-26-021306 |
| Exhibit: ex10-1.htm | 0001493152-26-021306 |
| Exhibit: ex10-3.htm | 0001493152-26-021306 |
| Document: form8-k.htm | 0001493152-26-021306 |
| Document: 0001493152-26-021306-index-headers.html | 0001493152-26-021306 |
| Document: 0001493152-26-021306-index.html | 0001493152-26-021306 |
| Document: 0001493152-26-021306.txt | 0001493152-26-021306 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | — | awaiting T+60 | — | — |
Oct 13, 2026 13d ago | 8-K | $0.0200 | awaiting T+60 | — | $0.0157 (−21.50%) |
Jul 14, 2026 14w ago | 8-K | $0.0400 $0.0200 | ▼ −50.00% | ▼ −52.79% | $0.0157 (−60.75%) |
Jun 29, 2026 17w ago | 8-K | $0.0400 $0.0245 | ▲ +38.75% | ▲ +42.59% | $0.0157 (+60.75%) |
May 5, 2026 24w ago | 8-K | $0.0400 $0.0400 | · 0.00% | ▼ −2.06% | $0.0157 (−60.75%) |
Apr 16, 2026 27w ago | 8-K | $0.0400 $0.0360 | ▼ −10.00% | ▼ −17.05% | $0.0157 (−60.75%) |
Apr 2, 2026 29w ago | 8-K | $0.0400 $0.0400 | · 0.00% | ▼ −14.16% | $0.0157 (−60.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers